<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1011419</article-id><article-id pub-id-type="publisher-id">ACM-38882</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201100000_41670034.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  微小RNA-744在动脉粥样硬化患者中表达的诊断和预后意义评估
  Diagnostic and Prognostic Significance of microRNA-744 Expression in Patients with Atherosclerosis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>伟</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>白</surname><given-names>蓓蓓</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>海萍</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院神经内科，山东 青岛</addr-line></aff><aff id="aff3"><addr-line>诸城市人民医院，山东 潍坊</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>11</month><year>2020</year></pub-date><volume>10</volume><issue>11</issue><fpage>2748</fpage><lpage>2755</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：动脉粥样硬化(Atherosclerosis, AS)是一种常见的血管疾病，是冠心病、缺血性心肌病、心力衰竭、血栓栓塞病的病理基础，具有较高的发病率和死亡率。近期大量的研究证明microRNAs (miRNAs)在AS的诊断和预后中发挥着至关重要的作用。本研究通过检测miR-744在AS中的表达情况，进一步评估miR-744对AS诊断和预后价值的影响。方法：采用荧光定量PCR技术检测120例AS患者和58例健康对照人群血清中miR-744的表达情况。通过受试者工作特征曲线(ROC曲线)分析miR-744的诊断的价值。使用Spearman相关系数评估miR-744与颈动脉内膜–中膜厚度(CIMT)的相关性，利用Kaplan-Meier生存曲线和多因素Cox回归分析miR-744在AS中的预后价值。结果：相较于健康对照组，AS患者血清中miR-744的表达水平显著降低(P &lt; 0.001)，且miR-744的表达水平与CIMT值呈显著负相关性(r = −0.776, P &lt; 0.001)。ROC曲线的AUC为0.887，特异性为93.33%，敏感性为82.85%，证实miR-744可能是AS的潜在的良好诊断标志物。生存分析表明miR-744低表达的患者发生心血管事件的概率较高(log rank P = 0.005)，miR-744可能是AS的潜在预后标志物(HR = 2.680, 95%CI = 1.105~6.503, P = 0.029)。结论：miR-744的低表达可能是良好的AS诊断标志物，并且与AS的不良预后相关。
    Objective: Atherosclerosis (AS) is a common vascular disease that is the pathological basis of coronary heart disease, ischemic cardiomyopathy, heart failure, thromboembolic disease, and has high morbidity and mortality. A large number of recent studies have demonstrated that microRNAs (miRNAs) play a crucial role in the diagnosis and prognosis of AS. The aim of this study was to examine the expression level of miR-744 in AS and to evaluate the diagnostic and prognostic value of miR-744 in AS. Methods: The expression of miR-744 in serum of AS patients and healthy control group was detected by fluorescence quantitative PCR. The diagnostic value of miR-744 was analyzed by the ROC curve. Spearman correlation coefficient was used to evaluate the correlation between miR-744 and carotid intima-media thickness (CIMT), and Kaplan-Meier survival curve and Multivariate Cox regression were used to analyze the prognostic value of miR-744 in AS. Results: Compared with the healthy control group, the expression level of miR-744 in the serum of AS patients was significantly reduced (P &lt; 0.001), and the expression level of miR-744 was negatively correlated with the CIMT value (r = −0.776, P &lt; 0.001). miR-744 is confirmed to be a potential good diagnostic marker for AS. The AUC of ROC curve is 0.887, the specificity is 93.33%, and the sensitivity is 82.85%. Survival analysis showed that low expression of miR-744 predicted a higher probability of cardiovascular events (log rank P = 0.005), and miR-744 might be a potential prognostic marker of AS (HR = 2.680, 95%CI = 1.105 - 6.503, P = 0.029). Conclusion: The low expression of miR-744 is a good diagnostic marker for AS, and is related to the poor prognosis of AS. 
  
 
</p></abstract><kwd-group><kwd>动脉粥样硬化，miR-744，诊断，预后, AS</kwd><kwd> miR-744</kwd><kwd> Diagnosis</kwd><kwd> Prognosis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：动脉粥样硬化(Atherosclerosis, AS)是一种常见的血管疾病，是冠心病、缺血性心肌病、心力衰竭、血栓栓塞病的病理基础，具有较高的发病率和死亡率。近期大量的研究证明microRNAs (miRNAs)在AS的诊断和预后中发挥着至关重要的作用。本研究通过检测miR-744在AS中的表达情况，进一步评估miR-744对AS诊断和预后价值的影响。方法：采用荧光定量PCR技术检测120例AS患者和58例健康对照人群血清中miR-744的表达情况。通过受试者工作特征曲线(ROC曲线)分析miR-744的诊断的价值。使用Spearman相关系数评估miR-744与颈动脉内膜–中膜厚度(CIMT)的相关性，利用Kaplan-Meier生存曲线和多因素Cox回归分析miR-744在AS中的预后价值。结果：相较于健康对照组，AS患者血清中miR-744的表达水平显著降低(P &lt; 0.001)，且miR-744的表达水平与CIMT值呈显著负相关性(r = −0.776, P &lt; 0.001)。ROC曲线的AUC为0.887，特异性为93.33%，敏感性为82.85%，证实miR-744可能是AS的潜在的良好诊断标志物。生存分析表明miR-744低表达的患者发生心血管事件的概率较高(log rank P = 0.005)，miR-744可能是AS的潜在预后标志物(HR = 2.680, 95%CI = 1.105~6.503, P = 0.029)。结论：miR-744的低表达可能是良好的AS诊断标志物，并且与AS的不良预后相关。</p></sec><sec id="s2"><title>关键词</title><p>动脉粥样硬化，miR-744，诊断，预后</p></sec><sec id="s3"><title>Diagnostic and Prognostic Significance of microRNA-744 Expression in Patients with Atherosclerosis<sup> </sup></title><p>Wei Liu<sup>1*</sup>, Beibei Bai<sup>2</sup>, Haiping Wang<sup>1#</sup></p><p><sup>1</sup>Department of Neurology, The Affiliated Hospital of Medical College Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Zhucheng People’s Hospital, Weifang Shandong</p><p><img src="//html.hanspub.org/file/53-1571657x5_hanspub.png" /></p><p>Received: Nov. 2<sup>nd</sup>, 2020; accepted: Nov. 20<sup>th</sup>, 2020; published: Nov. 27<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/53-1571657x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: Atherosclerosis (AS) is a common vascular disease that is the pathological basis of coronary heart disease, ischemic cardiomyopathy, heart failure, thromboembolic disease, and has high morbidity and mortality. A large number of recent studies have demonstrated that microRNAs (miRNAs) play a crucial role in the diagnosis and prognosis of AS. The aim of this study was to examine the expression level of miR-744 in AS and to evaluate the diagnostic and prognostic value of miR-744 in AS. Methods: The expression of miR-744 in serum of AS patients and healthy control group was detected by fluorescence quantitative PCR. The diagnostic value of miR-744 was analyzed by the ROC curve. Spearman correlation coefficient was used to evaluate the correlation between miR-744 and carotid intima-media thickness (CIMT), and Kaplan-Meier survival curve and Multivariate Cox regression were used to analyze the prognostic value of miR-744 in AS. Results: Compared with the healthy control group, the expression level of miR-744 in the serum of AS patients was significantly reduced (P &lt; 0.001), and the expression level of miR-744 was negatively correlated with the CIMT value (r = −0.776, P &lt; 0.001). miR-744 is confirmed to be a potential good diagnostic marker for AS. The AUC of ROC curve is 0.887, the specificity is 93.33%, and the sensitivity is 82.85%. Survival analysis showed that low expression of miR-744 predicted a higher probability of cardiovascular events (log rank P = 0.005), and miR-744 might be a potential prognostic marker of AS (HR = 2.680, 95%CI = 1.105 - 6.503, P = 0.029). Conclusion: The low expression of miR-744 is a good diagnostic marker for AS, and is related to the poor prognosis of AS.</p><p>Keywords:AS, miR-744, Diagnosis, Prognosis</p><disp-formula id="hanspub.38882-formula59"><graphic xlink:href="//html.hanspub.org/file/53-1571657x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/53-1571657x8_hanspub.png" /> <img src="//html.hanspub.org/file/53-1571657x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>动脉粥样硬化(Atherosclerosis, AS)作为全球老年人发病和死亡的主要原因，是一种涉及到动脉血管内皮下层的脂质充盈和巨噬细胞积累的全身慢性炎症性疾病。AS的特征包括高脂血症、巨噬细胞的聚集、泡沫细胞的形成以及炎症的发生。脂质巨噬细胞泡沫细胞会首先聚集在动脉壁上，并引发炎症，促进斑块的形成，最终导致AS的发生 [<xref ref-type="bibr" rid="hanspub.38882-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.38882-ref2">2</xref>]。部分AS患者的前期是没有任何症状，当AS发生后会引起心肌梗死、中风和外周动脉疾病等常见的并发症，具有较高的发病率和死亡率。因此需要对该病进行准确的诊断和预后评估，为AS的治疗提供新的治疗手段。</p><p>MicroRNAs (miRNAs)是一种内源性、非编码的单链RNA，长度约为22~25个核苷酸，通过与靶基因的3’非翻译区结合来抑制基因的表达，从而抑制其翻译或促进降解。miRNA的主要作用在癌症中已经被大量研究和报道，而最近的研究表明，这些小分子与心血管疾病的发生和发展密切相关，是良好的诊断和预后生物标志物以及治疗靶点。比如：miR-155通过靶向SOCS1增强STAT3和NF-κB信号通路从而增强AS的发生 [<xref ref-type="bibr" rid="hanspub.38882-ref3">3</xref>]。上调miR-206可以通过调控FOXP1诱导血管平滑肌细胞的凋亡，降低AS发生的风险 [<xref ref-type="bibr" rid="hanspub.38882-ref4">4</xref>]。</p><p>最近Wang等人报道指出miR-425和miR-744通过调控TGFβ1的表达作为心肌纤维化的负调控因子，同时血浆外泌体中的miR-425和miR-744的水平成为预测心肌纤维化和心力衰竭的生物标志物 [<xref ref-type="bibr" rid="hanspub.38882-ref5">5</xref>]。既然miR-744和miR-425可以显著的影响AS的常见并发症心力衰竭，因此我们推测miR-744和miR-425可以影响AS的发生和进展。miR-425通过抑制Notch和激活VEGF/p38信号通路阻断抗血管生成，从而影响AS已经被证实 [<xref ref-type="bibr" rid="hanspub.38882-ref6">6</xref>]，而miR-744在AS中的作用及其机制是未被证明以及阐述。</p><p>在本研究中，我们检测了58名健康对照人群和120名无症状的AS患者血清中miR-744的表达情况，通过分析受试者的临床数据对miR-744在AS患者中的诊断和预后价值进行评估。</p></sec><sec id="s6"><title>2. 材料与方法</title><sec id="s6_1"><title>2.1. 研究总体和样本收集</title><p>研究对象为从2008年1月份至2013年1月份在青岛大学附属医院检测的120名无症状AS患者以及58名健康志愿者，并以健康志愿者作为对照组。研究中纳入的受试者人群排除了被诊断为血管瘤、急性心肌梗死、心力衰竭、高血压、心绞痛、中风等具有严重心血管疾病的患者。本研究在经过青岛大学附属医院医学伦理委员会批准，所有受试者知情同意下进行。对所有受试者进行体格检查，记录所有受试者的年龄、体重、身高以及颈总动脉内膜–中膜厚度(CIMT)，采集所有受试者的血液并离心保存血清。</p></sec><sec id="s6_2"><title>2.2. RNA提取及实时荧光定量PCR</title><p>根据说明书的要求，使用TRIzol (Invitrogen, USA)提取AS患者和健康对照人群血清中总RNA，通过逆转录试剂盒将提取的RNA反转成cDNA，并使用SYBR green I Master Mix 试剂盒(Invitrogen, USA)在ABI 7300 qRT-PCR仪上进行扩增反应。反应条件为：95℃ 15 min；94℃ 15 s；55℃ 30 s，共40个循环。反应以U6作为miRNA表达量的内参，且其相对表达量用2−ΔΔCt的方法进行计算。使用的引物序列如下：miR-744正向：5′-ACACTCCAGCTGGGT GCGGGGCTAGGGCTAAC-3′；反向：5′-CTCAACTGGTGTCGTGGA-3′，U6正向：5′-GCTTCGGCAGCACATATACTAAAAT-3′；反向：5′-CTCAACTGGTGTCGTGGA-3′。</p></sec><sec id="s6_3"><title>2.3. 随访方案及内容</title><p>本研究的随访事件终点为2018年1月31日，通过为期5年的随访调查，并以最新发布的心血管终点事件的定义，记录AS患者因为发生心血管终点事件情况，包括心肌梗死、卒中、急性心衰、不稳定型心绞痛、短暂性脑缺血发作、冠状动脉介入治疗等心血管事件引发的的住院、死亡。在随访结束后绘制患者发生心血管不良事件的生存曲线。</p></sec><sec id="s6_4"><title>2.4. 统计学分析</title><p>本实验所有数据和分析均采用SPSS 21.0软件以及GraphPad Prism 7软件进行，组间比较采用Student’s t test，ROC曲线对诊断价值进行评价，Spearman相关系数分析检测两个变量之间的关联程度及方向，通过Kaplan-Meier法和log-rank法检测miRNA对患者发生心血管终点事件的影响，Cox回归模型评估预后价值。所有数据当P &lt; 0.05时差异具有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 人口及临床资料</title><p>受试者的人口学特征和临床数据如表1所示：健康对照人群和AS患者在体质量指数、年龄、性别、总胆固醇、高密度脂蛋白、低密度脂蛋白、收缩压、舒张压、甘油三酯等指标并无显著差异(P &gt; 0.05)，但是炎症标志物C反应蛋白在两组之间存在显著性差异，且AS患者组的浓度显著高于健康对照组(P &lt; 0.05)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Demographic and clinical characteristics between group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >变量</th><th align="center" valign="middle" >健康对照 (n = 58)</th><th align="center" valign="middle" >AS患者 (n =120)</th><th align="center" valign="middle" >P value</th></tr></thead><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" >55 &#177; 2</td><td align="center" valign="middle" >54 &#177; 3</td><td align="center" valign="middle" >0.658</td></tr><tr><td align="center" valign="middle" >性别(男/女)</td><td align="center" valign="middle" >27/31</td><td align="center" valign="middle" >59/61</td><td align="center" valign="middle" >0.745</td></tr><tr><td align="center" valign="middle" >体质量指数(kg/m<sup>2</sup>)</td><td align="center" valign="middle" >24.27 &#177; 2.66</td><td align="center" valign="middle" >23.86 &#177; 1.72</td><td align="center" valign="middle" >0.289</td></tr><tr><td align="center" valign="middle" >总胆固醇(mg/dl)</td><td align="center" valign="middle" >209.07 &#177; 8.59</td><td align="center" valign="middle" >208.11 &#177; 13.29</td><td align="center" valign="middle" >0.562</td></tr><tr><td align="center" valign="middle" >高密度脂蛋白(mg/dl)</td><td align="center" valign="middle" >49.76 &#177; 7.71</td><td align="center" valign="middle" >51.96 &#177; 13.29</td><td align="center" valign="middle" >0.166</td></tr><tr><td align="center" valign="middle" >低密度脂蛋白(mg/dl)</td><td align="center" valign="middle" >118.55 &#177; 15.49</td><td align="center" valign="middle" >117.08 &#177; 16.07</td><td align="center" valign="middle" >0.557</td></tr><tr><td align="center" valign="middle" >甘油三酯(mg/dl)</td><td align="center" valign="middle" >148.33 &#177; 24.43</td><td align="center" valign="middle" >150.13 &#177; 12.57</td><td align="center" valign="middle" >0.599</td></tr><tr><td align="center" valign="middle" >收缩压(mmHg)</td><td align="center" valign="middle" >135.33 &#177; 10.14</td><td align="center" valign="middle" >133.83 &#177; 12.24</td><td align="center" valign="middle" >0.389</td></tr><tr><td align="center" valign="middle" >舒张压(mmHg)</td><td align="center" valign="middle" >88.45 &#177; 5.92</td><td align="center" valign="middle" >89.54 &#177; 5.63</td><td align="center" valign="middle" >0.234</td></tr><tr><td align="center" valign="middle" >C反应蛋白(mg/l)</td><td align="center" valign="middle" >6.20 &#177; 1.74</td><td align="center" valign="middle" >10.07 &#177; 1.79</td><td align="center" valign="middle" >0.000</td></tr></tbody></table></table-wrap><p>表1. 组间的人口统计学和临床特征</p></sec><sec id="s7_2"><title>3.2. AS患者血清中miR-744的表达水平</title><p>为了研究AS患者与健康对照组血清中miR-744表达水平是否存在差异，我们首先测量了178例受试者血清中miR-744的表达水平。如图1所示：与健康对照组相比，AS患者样本血清中miR-744的表达水平显著降低(P &lt; 0.05，图1)。说明miR-744在AS的进展中发挥着至关重要的作用。</p><p>图1. miR-744在AS患者中的相对表达量。<sup>***</sup>P &lt; 0.001</p></sec><sec id="s7_3"><title>3.3. CIMT与AS患者血清中miR-744表达量之间的相关性</title><p>AS是一种脂质物沿动脉壁聚集的情况，这种脂质物质会变厚、变硬(形成钙沉淀)，最终可能阻塞动脉。CIMT是美国心脏协会和美国心脏病学会推荐的一种超声检查，可定量测量颈动脉内膜–中膜厚度用于评估个体心血管疾病的风险，因为它的非侵入，快速，可复制，无风险的特点，许多流行病学研究证实，CIMT是亚临床AS的一个指标。本研究中无症状的AS患者CIMT均值为0.8157 &#177; 0.1920 mm，进一步通过Spearman相关系数分析检测miR-744与CIMT之间的相关性，研究结果证明miR-744的表达量与CIMT值为显著负相关(r = −0.776, P &lt; 0.001，图2)。</p><p>图2. AS患者中miR-744的表达水平与CIMT值之间的相关性</p></sec><sec id="s7_4"><title>3.4. miR-744在AS患者血清中的诊断价值的评估</title><p>ROC曲线在医学研究中普遍存在，可用于常见疾病包括肿瘤、心血管等疾病的评估筛选、诊断、预后和预测生物标志物，旨在同时显示连续诊断试验的每个可能值，作为评价生物标志物诊断能力最常用的图形工具，它能提供了生物标志物的敏感性和特异性。在本研究中我们通过ROC曲线评估miR-744在AS患者中的诊断价值，结果显示：ROC的截止值为1.31，曲线下面积AUC为0.887，敏感度为82.85%，特异性为93.33% (图3)，评估结果预示着miR-744在AS患者中具有较高的诊断价值。</p><p>图3. ROC曲线分析AUC为0.887，敏感性为82.85%，特异性为93.33%</p></sec><sec id="s7_5"><title>3.5. miR-744在AS患者中的预后作用</title><p>将miR-744表达水平的中位数作为截断值，将患者分为血清miR-744高低表达两组，同时根据患者在5年随访过程中发生心血管终点事件的情况绘制生存曲线，探讨AS患者发生心血管不良事件与miR-744表达量之间的关系，并对miR-744的预后价值进行评估。研究结果表明：相较于miR-744高表达，miR-744低表达患者发生心血管不良事件的概率显著增高(log rank test P = 0.005，图4)。</p><p>图4. 不同miR-744表达量的AS患者Kaplan-Meier生存曲线图</p><p>根据受试者的临床特征和miR-744的表达情况采用多因素Cox回归分析miR-744在AS中的预后价值。研究结果显示：miR-744是AS患者良好的预后标志物(P &lt; 0.05，表2)。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Multivariate Cox regression analysis for the overall survival of AS patients ( x &#175; &#177; s , n = 120</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >参数</th><th align="center" valign="middle"  colspan="3"  >多因素分析</th></tr></thead><tr><td align="center" valign="middle" >HR</td><td align="center" valign="middle" >95%CI</td><td align="center" valign="middle" >P value</td></tr><tr><td align="center" valign="middle" >miR-744</td><td align="center" valign="middle" >2.680</td><td align="center" valign="middle" >1.105~6.503</td><td align="center" valign="middle" >0.029</td></tr><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >0.707</td><td align="center" valign="middle" >0.320~1.561</td><td align="center" valign="middle" >0.3.91</td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" >0.929</td><td align="center" valign="middle" >0.448~1.923</td><td align="center" valign="middle" >0.842</td></tr><tr><td align="center" valign="middle" >体质量指数(kg/m<sup>2</sup>)</td><td align="center" valign="middle" >0.830</td><td align="center" valign="middle" >0.339~2.032</td><td align="center" valign="middle" >0.683</td></tr><tr><td align="center" valign="middle" >总胆固醇(mg/dl)</td><td align="center" valign="middle" >0.597</td><td align="center" valign="middle" >0.262~1.359</td><td align="center" valign="middle" >0.219</td></tr><tr><td align="center" valign="middle" >高密度脂蛋白(mg/dl)</td><td align="center" valign="middle" >0.891</td><td align="center" valign="middle" >0.430~1.846</td><td align="center" valign="middle" >0.757</td></tr><tr><td align="center" valign="middle" >低密度脂蛋白(mg/dl)</td><td align="center" valign="middle" >0.433</td><td align="center" valign="middle" >0.152~1.230</td><td align="center" valign="middle" >0.116</td></tr><tr><td align="center" valign="middle" >甘油三酯(mg/dl)</td><td align="center" valign="middle" >0.768</td><td align="center" valign="middle" >0.317~1.860</td><td align="center" valign="middle" >0.559</td></tr><tr><td align="center" valign="middle" >收缩压(mmHg)</td><td align="center" valign="middle" >0.886</td><td align="center" valign="middle" >0.430~1.825</td><td align="center" valign="middle" >0.742</td></tr><tr><td align="center" valign="middle" >舒张压(mmHg)</td><td align="center" valign="middle" >0.442</td><td align="center" valign="middle" >0.161~1.217</td><td align="center" valign="middle" >0.114</td></tr><tr><td align="center" valign="middle" >C反应蛋白(mg/l)</td><td align="center" valign="middle" >2.978</td><td align="center" valign="middle" >1.029~8.615</td><td align="center" valign="middle" >0.044</td></tr><tr><td align="center" valign="middle" >CIMT (cm)</td><td align="center" valign="middle" >3.723</td><td align="center" valign="middle" >1.131~12.255</td><td align="center" valign="middle" >0.031</td></tr></tbody></table></table-wrap><p>表2. AS患者总体生存率的多因素Cox回归分析( x &#175; &#177; s , n = 120)</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>AS的过程可以在出生后就开始，并在早期被发现 [<xref ref-type="bibr" rid="hanspub.38882-ref7">7</xref>]。随后AS往往表现为更严重的临床事件，比如急性和慢性形式的动脉粥样硬化、缺血性中风、外周动脉疾病。且AS首次发生时大数是致命且无任何征兆的 [<xref ref-type="bibr" rid="hanspub.38882-ref8">8</xref>]。因此对AS临床表现前的高危人群检测是研究的重点，在适当的时机采取有效的干预措施至关重要的。</p><p>miR-744位于17号染色体上。据报道miR-744参与了导致人类疾病发生发展的多个过程，包括癌症和心血管疾病等。比如Tan等人证明miR-744是肝癌患者的一个潜在预后标志物 [<xref ref-type="bibr" rid="hanspub.38882-ref9">9</xref>]。Fang等人证明miR-744通过转录调控ARHGAP5在鼻咽癌进展和转移中发挥原癌基因的功能 [<xref ref-type="bibr" rid="hanspub.38882-ref10">10</xref>]。值的注意的是Chavali等人筛选了在心力衰竭病人中异常表达的miRNA，其中包括了miR-744 [<xref ref-type="bibr" rid="hanspub.38882-ref11">11</xref>]。同样Wang等人发现miR-425和miR-744通过抑制TGFβ1表达而起到了心脏纤维化的负调控作用，并且血浆外泌体中的miR-425和miR-744的水平有可能成为预测心脏纤维化和心力衰竭的生物标志物 [<xref ref-type="bibr" rid="hanspub.38882-ref5">5</xref>]。有趣的是我们首次证实了与健康对照人员相比，miR-744在AS患者中的表达水平显著下降，而这与已有研究中miR-744在AS常见并发症中的结果一致。研究结果证实miR-744在AS的进展中可能发挥着重要的作用。</p><p>研究结果还证实了与健康对照人员相比，患者中的炎症非特异性标志物CRP浓度显著升高。既往的研究已经证实AS是由炎症反应引起的多因素疾病，炎症过程有助于急性AS血栓事件的发生，与心血管疾病密切相关，例如AS、高血压、心肌梗死等。此外，CIMT是美国心脏协会和心脏病学会推荐的超声检测，可作为AS早期检测和跟踪的工具，因具有实时、方便、快速、安全、无创的优点，越来越受到医生的青睐，CIMT的增加被认为是亚临床AS的重要指标，在我们的研究中血清miR-744较低的患者CIMT值较高，两者呈显著的负相关性。实验结果再次证实了AS与miR-744的低表达密切相关。</p><p>miRNA在AS中的诊断和预后价值已经被广泛的研究，因此我们进一步评估miR-744在AS进展中的临床作用和意义。通过构建ROC曲线评估miR-744的诊断价值，AUC值为0.887，特异性为93.33%，敏感性为82.8%截止值为1.31，提示miR-744可能是AS的良好诊断标志物。Kaplan-Meier生存曲线分析显示，miR-744表达相对较低的患者具有较高的发生心血管不良事件的概率。多因素Cox回归分析证实miR-744的低表达是AS不良预后的重要指标。实验结果进一步证实了miR-744也是AS的良好预后标志物。虽然通过一系列实验证明了miR-744可能是AS潜在的诊断和预后标志物，但是本研究还存在一些局限性，首先样本量相对较小，这可能会降低我们研究的统计价值，其次miR-744在AS发生发展中的机制尚不清楚，还需要进一步研究。</p><p>总之，我们结合临床资料和实验研究确定了miR-744在AS进展的临床意义和作用，研究结果证实miR-744在AS患者血清中是低表达的，同时miR-744表达水平的下降与AS的不良预后相关，且是AS诊断的潜在良好标志物。</p></sec><sec id="s9"><title>文章引用</title><p>刘 伟,白蓓蓓,王海萍. 微小RNA-744在动脉粥样硬化患者中表达的诊断和预后意义评估Diagnostic and Prognostic Significance of microRNA-744 Expression in Patients with Atherosclerosis[J]. 临床医学进展, 2020, 10(11): 2748-2755. https://doi.org/10.12677/ACM.2020.1011419</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.38882-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Razani, B., Feng, C., Coleman, T., Emanuel, R., Wen, H., Hwang, S., Ting, J.P., Virgin, H.W., Kastan, M.B. and Semenkovich, C.F. (2012) Autophagy Links Inflammasomes to Atherosclerotic Progression. Cell Metabolism, 15, 534-544.  
&lt;br&gt;https://doi.org/10.1016/j.cmet.2012.02.011</mixed-citation></ref><ref id="hanspub.38882-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Robinet, P., Ritchey, B. and Smith, J.D. (2013) Physiological Difference in Autophagic Flux in Macrophages from 2 Mouse Strains Regulates Cholesterol Ester Metabolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 33, 903-910.  
&lt;br&gt;https://doi.org/10.1161/ATVBAHA.112.301041</mixed-citation></ref><ref id="hanspub.38882-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Yang, Y., Yang, L., Liang, X. and Zhu, G. (2015) MicroRNA-155 Promotes Atherosclerosis Inflammation via Targeting SOCS1. Cellular Physiology and Biochemistry, 36, 1371-1381. &lt;br&gt;https://doi.org/10.1159/000430303</mixed-citation></ref><ref id="hanspub.38882-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Xing, T., Du, L., Zhuang, X., Zhang, L., Hao, J. and Wang, J. (2017) Upregulation of microRNA-206 Induces Apoptosis of Vascular Smooth Muscle Cells and Decreases Risk of Atherosclerosis through Modulating FOXP1. Experimental and Therapeutic Medicine, 14, 4097-4103. &lt;br&gt;https://doi.org/10.3892/etm.2017.5071</mixed-citation></ref><ref id="hanspub.38882-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Wang, L., Liu, J., Xu, B., Liu, Y.L. and Liu, Z. (2018) Reduced Exosome miR-425 and miR-744 in the Plasma Represents the Progression of Fibrosis and Heart Failure. The Kaohsiung Journal of Medical Sciences, 34, 626-633.  
&lt;br&gt;https://doi.org/10.1016/j.kjms.2018.05.008</mixed-citation></ref><ref id="hanspub.38882-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Gao, Y., Yin, Y., Xing, X., Zhao, Z., Lu, Y., Sun, Y., Zhuang, Z., Wang, M., Ji, W. and He, Y. (2016) Arsenic-Induced Anti-Angiogenesis via miR-425-5p-Regulated CCM3. Toxicology Letters, 254, 22-31.  
&lt;br&gt;https://doi.org/10.1016/j.toxlet.2016.04.023</mixed-citation></ref><ref id="hanspub.38882-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Ganz, P., Creager, M.A., Fang, J.C., Mcconnell, M.V., Lee, R.T., Libby, P. and Selwyn, A.P. (1996) Pathogenic Mechanisms of Atherosclerosis: Effect of Lipid Lowering on the Biology of Atherosclerosis. The American Journal of Medicine, 101, 4A10S-16S. &lt;br&gt;https://doi.org/10.1016/S0002-9343(96)00316-6</mixed-citation></ref><ref id="hanspub.38882-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Chambless, L., Keil, U., Dobson, A., Mahonen, M., Kuulasmaa, K., Rajakangas, A.M., Lowel, H. and Tunstall-Pedoe, H. (1997) Population versus Clinical View of Case Fatality from Acute Coronary Heart Disease: Results from the WHO MONICA Project 1985-1990. Multinational Monitoring of Trends and Determinants in Cardiovascular Disease. Circulation, 96, 3849-3859. &lt;br&gt;https://doi.org/10.1161/01.CIR.96.11.3849</mixed-citation></ref><ref id="hanspub.38882-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Tan, Y.L., Bai, Z.G., Zou, W.L., Ma, X.M., Wang, T.T., Guo, W., Liu, J., Li, J.S., Jie, Y., Zang, Y.J. and Zhang, Z.T. (2015) miR-744 Is a Potential Prognostic Marker in Patients with Hepatocellular Carcinoma. Clinics and Research in Hepatology and Gastroenterology, 39, 359-365. &lt;br&gt;https://doi.org/10.1016/j.clinre.2014.09.010</mixed-citation></ref><ref id="hanspub.38882-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Fang, Y., Zhu, X., Wang, J., Li, N., Li, D., Sakib, N., Sha, Z. and Song, W. (2015) MiR-744 Functions as a Proto-Oncogene in Nasopharyngeal Carcinoma Progression and Metastasis via Transcriptional Control of ARHGAP5. Oncotarget, 6, 13164-13175. &lt;br&gt;https://doi.org/10.18632/oncotarget.3754</mixed-citation></ref><ref id="hanspub.38882-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Chavali, V., Tyagi, S.C. and Mishra, P.K. (2014) Differential Expression of Dicer, miRNAs, and Inflammatory Markers in Diabetic Ins2+/− Akita Hearts. Cell Biochemistry and Biophysics, 68, 25-35.  
&lt;br&gt;https://doi.org/10.1007/s12013-013-9679-4</mixed-citation></ref></ref-list></back></article>